| Literature DB >> 23537964 |
Adel Nada1, Gary A Gintant, Robert Kleiman, David E Gutstein, Christer Gottfridsson, Eric L Michelson, Colette Strnadova, Matthew Killeen, Mary Jane Geiger, Mónica L Fiszman, Luana Pesco Koplowitz, Glenn F Carlson, Ignacio Rodriguez, Philip T Sager.
Abstract
Recent advances in electrocardiographic monitoring and waveform analysis have significantly improved the ability to detect drug-induced changes in cardiac repolarization manifested as changes in the QT/corrected QT interval. These advances have also improved the ability to detect drug-induced changes in cardiac conduction. This White Paper summarizes current opinion, reached by consensus among experts at the Cardiac Safety Research Consortium, on the assessment of electrocardiogram-based safety measurements of the PR and QRS intervals, representing atrioventricular and ventricular conduction, respectively, during drug development.Entities:
Mesh：
Substances：
Year: 2013 PMID： 23537964 DOI： 10.1016/j.ahj.2013.01.011
Source DB: PubMed Journal: Am Heart J ISSN： 0002-8703 Impact factor: 4.749